Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream

NCT02685592 is registered in ClinicalTrials.gov with Joint Authority for Päijät-Häme Social and Health Care as lead sponsor.

NCT NCT02685592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02685592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream
Lead sponsor
Joint Authority for Päijät-Häme Social and Health Care
Phase
Phase 4
Overall status
Completed
Start date
February 29, 2016
Completion date
March 31, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lentigo maligna